

The group already had 147 centers and was the global leader in plasma collection for the production of plasma derivatives

Grifols agrees to purchase three plasma donation centers in the United States from Canada's Cangene

- *Once the transaction is concluded, Grifols has 150 plasmapheresis centers*
- *The transaction is consistent with the investment plan designed to ensure the group's growth organically and through strategic acquisitions.*

Barcelona, September 17, 2012.- Grifols, (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) the third largest global producer of plasma therapies, has signed a purchase agreement with the Canadian biopharmaceutical company Cangene Corporation for the acquisition of its three plasma donation centers located in the United States.

The transaction enable Grifols to bolster its global leadership in plasma collection and benefit its vertical integration strategy while guaranteeing its needs in terms of raw materials and its ability to address the growing demand for treatments with plasma proteins thus benefiting patients. This operation is also consistent with the investment plan set up for the period to 2015; the objective of this plan is to guarantee the group's sustained growth over the long term, both organically and through strategic acquisitions.

Due to the acquisition Grifols now owns 150 plasma donation centers in the United States, which will enable it to increase its plasma collection capacity in line with its planned capacity increase. The installed plasma fractionation capacity at the end of 2011 was 8.5 million liters of plasma per year split between plants in the United States and Spain, although projected capital (CAPEX) expenditures call for this capacity to exceed 12 million liters per year by 2016.

Moreover, with the recent start of operations at a second plasma analysis laboratory in San Marcos (Texas) in addition to the company's existing laboratories in Austin (Texas), Grifols also has the resources needed for the analysis of samples.

About Grifols

Grifols, with presence in more than 100 countries, is a global pharmaceutical company specializing in the Hemotherapy sector, the medical discipline that treats disease using blood components. The company's class A shares have been listed on the Spanish Stock Exchange (MCE:GRF) since 2006 and have been part of the Ibex-35 since 2008. In 2011, the company listed non-voting class B shares on the Mercado Continuo (MCE:GRF.P) and in NASDAQ-United States via ADRs (NASDAQ: GRFS).

Grifols is the third company worldwide in plasma protein therapies, in terms of capacity after the recent purchase of Talecris, with a balanced and diversified range of products. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, as a result of on-going investment plans. Grifols is the world leader in plasma collection with 147 plasma donor centers in the United States to ensure a continued and reliable supply of human plasma for the production of plasma therapies. In terms of production capacity (fractionation), Grifols owns and operates several plants in Spain and the United States that allow it to respond to the growing market demand. Grifols' sustained growth will be supported by a strong presence in the United States, Canada and Europe.

About Cangene Corporation

Cangene Corporation (TSX: CNJ), headquartered in Winnipeg, Canada, is one of the nation's leading biopharmaceutical companies. It is focused on the development and commercialization of hospital and oncology clinic based therapeutics. Cangene's products are sold worldwide and include products that have been accepted into the U.S. Strategic National Stockpile (list of strategic medications in the United States). Cangene operates manufacturing facilities in Winnipeg, Manitoba and Baltimore, Maryland (through its subsidiary, Cangene BioPharma, Inc.). For more information about Cangene, visit the company's website at www.cangene.com

DISCLAIMER

The facts and figures contained in this report which do not refer to historical data are "projections and forward-looking statements". The words and expressions like "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "try to achieve", "estimate", "future" and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events. Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law.

This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.